特异性免疫治疗是唯一针对过敏性疾病病因的疗法，然而特异性免疫治疗仅针对特定过敏原，治疗周期长，且有发生超敏反应的风险，因此研发安全有效的广谱免疫治疗制剂对过敏性疾病防治具有重要意义。为此，我们创建了泛过敏原Profillin与人IL-10的嵌合蛋白LTT，旨在提高安全性的同时，促进免疫耐受的形成。前期多项动物实验证实LTT改善过敏性鼻炎及过敏性哮喘作用明显。虽然已知IL-10具有抑制人树突状细胞(DC)成熟及肥大细胞脱颗粒，促进Treg细胞产生的作用，但是LTT是否通过以上途径发挥作用并不清楚。为此，我们拟在DC、CD4+T细胞以及肥大细胞模型上，研究LTT对DC细胞表型，CD4+T细胞分化以及肥大细胞脱颗粒的影响，同时探讨嵌合蛋白发挥作用是否依赖IL-10受体及其下游信号通路的激活。从而深入解析嵌合蛋白LTT发挥免疫调节,诱导免疫耐受的机制，为广谱免疫治疗制剂的研制提供新的思路与典范。

Specific immunotherapy is the only treatment for allergic disease in etiology; however, it also has limitations: a) SIT is usually for a single and specific allergen, b) The treatment period is long, c) Exists the risk of hypersensitivity reactions. Therefore, exploring more safe and effective immunotherapy agents with broad spectrum is necessary. To this end, we created a chimeric protein combined pan-allergen profillin with human IL-10. The results of animal experiments confirmed that LTT improved allergic rhinitis and allergic asthma obviously in vivo. IL-10 is known to inhibit DC maturation and mast cell degranulation as well as promote Treg cells production. However, whether LTT can act as IL-10 in these ways is not clear. Therefore, we want to study LTT on human dendritic cells (DC), CD4+T cells and mast cell model. The Change of DC phenotype, CD4+T cell differentiation and the inhibited effect on mast cell degranulation by LTT will be investigated. Also, whether LTT exert its immunomodulatory effect depend on IL-10 receptor and its downstream signaling pathway activation will be discussed. This study will help us to illuminate the mechanism of chimeric protein LTT how to exert its immunomodulatory effects. Furthermore, it will provide a new model and idea for development of immunotherapy agents with a broad spectrum.